glp-1/gip receptor agonist Understand Dual Tirzepatide and Its Effect on Current Weight Loss Therapy Physiology and clinical applications of

In agreement with experimental studies, GLP-1 analogues, particularly liraglutide, sustain the maintenance of -cell function in obese individuals with early T2D, and these effects are presumably independent of weight loss (42, 43)

However, they are not a substitute for professional medical advice, diagnosis, or treatment

Approval for Diabetes and Weight Management Over the past decade, three GLP-1/GIP receptor agonists liraglutide, semaglutide, and tirzepatide initially approved by the FDA for adults with type 2 diabetes, have also gained FDA approval for chronic weight management in people without diabetes, provided they meet specific criteria: a BMI of 30, or 27 with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes

Sci 3 , 690705 (2020)

doi: 10.1007/s00125-009-1562-x

"Ozempic may come at a price 5-10% cheaper than Wegovy